Lupin Acquires Huminsulin from Eli Lilly to Enhance Diabetes Portfolio

Global pharma major Lupin Limited has announced the acquisition of Huminsulin® in India from Eli Lilly and Company to further enhance its diabetes portfolio. Lupin has been marketing the Huminsulin range of products through existing Distribution and Promotion Agreements with Lilly, India. The Huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and children. This acquisition is strategic to Lupin's ongoing efforts to expand its diabetes portfolio and provide high-quality, affordable healthcare to patients.